Oksaliplatin Kabi (Oxaliplatin)

Oxaliplatin exerts its anticancer effect by forming covalent DNA adducts that create intra‑ and inter‑strand cross‑links, thereby blocking DNA replication and transcription. The resulting DNA damage triggers cell‑cycle arrest and apoptosis in rapidly dividing tumour cells, while sparing most normal tissues.

The specific dose of Oksaliplatin Kabi is determined by the prescribing oncologist based on the patient’s body surface area, type of cancer, and treatment protocol. Dosing regimens are individualized and may be adjusted for renal function, prior toxicity, or combination with other agents.

Oxaliplatin is classified as contraindicated during pregnancy because it can cross the placenta and cause fetal toxicity. It is also not recommended for breastfeeding mothers, as the drug may be excreted in breast milk and affect the infant. Women of child‑bearing potential should use effective contraception during treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Compared with cisplatin, oxaliplatin has a different spectrum of activity and a lower incidence of nephrotoxicity, but it is more commonly associated with peripheral neuropathy. It is often preferred in colorectal cancer regimens because of its synergistic effect with fluoropyrimidines, whereas cisplatin remains a mainstay for testicular and head‑and‑neck cancers.

Oksaliplatin Kabi should be stored at controlled room temperature, below 25 °C, in its original packaging to protect from light and moisture. The product is supplied as a sterile powder for reconstitution; reconstituted solutions must be used promptly or stored according to the manufacturer’s instructions, typically refrigerated and protected from light.

The medication is supplied as a sterile powder that is reconstituted with a suitable diluent and administered intravenously, usually as an infusion over 2 hours. Administration is performed by qualified healthcare professionals in a clinical setting, with appropriate monitoring for infusion‑related reactions and vital signs throughout the procedure.

The most serious adverse events include severe peripheral neuropathy that may be irreversible, acute hypersensitivity reactions such as anaphylaxis, and hematologic toxicities like neutropenia or thrombocytopenia that increase infection or bleeding risk. Prompt recognition and management of these events are essential, and dose modifications may be required.

Oxaliplatin is contraindicated in patients with known hypersensitivity to platinum compounds, in pregnant or nursing women, and in individuals with severe pre‑existing neuropathy or uncontrolled renal impairment. It should also be used with caution in patients receiving other neurotoxic agents or those with compromised bone‑marrow function.